Published in Am J Cardiol on April 02, 2010
Effectiveness of percutaneous coronary intervention within 12 hours to 28 days of ST-elevation myocardial infarction in a real-world Chinese population. PLoS One (2013) 0.85
Relationship Between Anemia and Mortality Outcomes in a National Acute Coronary Syndrome Cohort: Insights From the UK Myocardial Ischemia National Audit Project Registry. J Am Heart Assoc (2016) 0.83
Impact of anemia on in-hospital, one-month and one-year mortality in patients with acute coronary syndrome from the Middle East. Clin Med Res (2012) 0.80
Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients. Int J Obes (Lond) (2013) 0.78
Correlation Between Haemoglobin Level and Electrocardiographic (ECG) Findings in Anaemia: A Cross-Sectional Study. J Clin Diagn Res (2014) 0.78
Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients. Acta Cardiol Sin (2016) 0.77
Six-month mortality and cardiac catheterization in non-ST-segment elevation myocardial infarction patients with anemia. Coron Artery Dis (2011) 0.77
Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. Sci Rep (2015) 0.76
Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry. PLoS One (2014) 0.76
Anemia and Acute Coronary Syndrome: Time for Intervention Studies. J Am Heart Assoc (2016) 0.75
Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysis. J Thorac Dis (2015) 0.75
Prevalence and prognostic significance of anemia in patients presenting for ST-elevation myocardial infarction in a Tunisian center. J Saudi Heart Assoc (2016) 0.75
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol (2011) 6.35
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol (2004) 5.67
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 4.62
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med (2002) 4.25
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet (2012) 4.02
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74
Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA (2012) 3.71
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol (2004) 3.67
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv (2011) 3.38
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation (2003) 3.22
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol (2005) 3.15
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med (2015) 2.97
Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension (2008) 2.89
Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation (2006) 2.88
In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol (2010) 2.85
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet (2009) 2.82
Patient safety and outcomes from live case demonstrations of interventional cardiology procedures. JACC Cardiovasc Interv (2012) 2.79
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol (2013) 2.64
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation (2008) 2.62
A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol (2010) 2.62
Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA (2011) 2.61
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation (2010) 2.54
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol (2011) 2.49